Adverts

Open Access Articles- Top Results for Azilsartan

Azilsartan

</th></tr>
Azilsartan medoxomil
File:Azilsartan.svg
Systematic (IUPAC) name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate
Clinical data
Trade names Edarbi
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611028
Licence data US FDA:link
  • C (1st trimester)
    D (2nd/3rd trimester) (US)
Oral
Identifiers
147403-03-0 7pxN
C09CA09
PubChem CID 9825285
ChemSpider 9413866 7pxY
UNII F9NUX55P23 7pxY
ChEBI CHEBI:68845 7pxN
ChEMBL CHEMBL57242 7pxN
Chemical data
Formula C25H20N4O5
456.46 g/mol
 14pxN (what is this?)  (verify)

Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension, developed by Takeda.

It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration approved azilsartan medoxomil for the treatment of high blood pressure in adults.[1] On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. [2]

Mechanism of action

Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

File:Azilsartan medoxomil.svg
Azilsartan medoxomil, the prodrug used, Edarbi

References

  1. ^ "FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration. February 25, 2011. Retrieved 2011-03-01. 
  2. ^ Notice of Decision for EDARBI

Lua error in package.lua at line 80: module 'Module:Buffer' not found.